{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:37:40Z","timestamp":1759624660892,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.eururo.2023.09.013","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T15:49:13Z","timestamp":1696434553000},"page":"545-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6929-6124","authenticated-orcid":false,"given":"Girish S.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian S.","family":"Wettstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.09.013_b0005","unstructured":"US Food and Drug Administration. FDA workshop: clinical trial design for non-muscle invasive bladder cancer (NMIBC). November 18\u201319, 2021. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-workshop-clinical-trial-design-non-muscle-invasive-bladder-cancer-nmibc-11182021."},{"key":"10.1016\/j.eururo.2023.09.013_b0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.09.013_b0015","doi-asserted-by":"crossref","unstructured":"Black PC, Tangen CM, Singh P, et al. Phase 2 Trial of atezolizumab in bacillus Calmette-Gu\u00e9rin\u2013unresponsive High-risk Non\u2013muscle-invasive bladder cancer: SWOG S1605. Eur Urol. 2023;84:535\u201344. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.004.","DOI":"10.1016\/j.eururo.2023.08.004"},{"key":"10.1016\/j.eururo.2023.09.013_b0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.09.013_b0025","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.09.013_b0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/bco2.220","article-title":"PemBla: a phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer","volume":"4","author":"Woodcock","year":"2023","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2023.09.013_b0035","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.euf.2021.09.005","article-title":"Sequential gemcitabine plus docetaxel is the standard second-line intravesical therapy for bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle invasive bladder cancer: con","volume":"8","author":"Grobet-Jeandin","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.09.013_b0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.09.013_b0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.euf.2021.07.018","article-title":"Sequential gemcitabine plus docetaxel is the standard second-line intravesical therapy for BCG-unresponsive non\u2013muscle-invasive bladder cancer: pro","volume":"8","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol Focus"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382303138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382303138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:58Z","timestamp":1759583638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382303138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S030228382303138X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.09.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.08.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}